SAN DIEGO, Dec. 29, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the publication of data documenting the successful pilot lot production and initiation of animal immunogenicity testing of a Vaxfectin(R)-adjuvanted DNA vaccine for H1N1 influenza before conventional vaccine manufacturers even received the seed virus needed to start production.
